Ionis Pharmaceuticals, Inc. Earnings Dividend

Ionis Pharmaceuticals, Inc.’s revenue jumped 86.98% since last year same period to $246.09Mn in the Q1 2026. On a quarterly growth basis, Ionis Pharmaceuticals, Inc. has generated 21.23% jump in its revenue since last 3-months.

Ionis Pharmaceuticals, Inc.’s net profit jumped 37.03% since last year same period to $-92.53Mn in the Q1 2026. On a quarterly growth basis, Ionis Pharmaceuticals, Inc. has generated 59.59% jump in its net profits since last 3-months.

Ionis Pharmaceuticals, Inc.’s net profit margin jumped 66.32% since last year same period to -37.6% in the Q1 2026. On a quarterly growth basis, Ionis Pharmaceuticals, Inc. has generated 66.67% jump in its net profit margins since last 3-months.

Ionis Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.78 - a 41.43% jump from last quarter’s estimates.

Ionis Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.78.

Ionis Pharmaceuticals, Inc.’s earning per share (EPS) jumped 67.23% since last year same period to -0.3 in the Q1 2026. This indicates that the Ionis Pharmaceuticals, Inc. has generated 67.23% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ionis Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ionis Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.68.